American Heart Association announces late-breaking research for Scientific Sessions 2026
The American Heart Association (AHA) has released a list of 23 late-breaking studies that will be presented at the AHA Scientific Sessions 2026 in Chicago from Nov. 6 to Nov. 9. The studies answer key questions in patient care and evaluate new technologies, drugs and care approaches.
LBS.01: The Dr. Eugene Braunwald Late-Breaking Science Session. Translating Science into Prevention: Lessons from Landmark Trials
Saturday, Nov. 7, 2026, 8:30 to 9:45 a.m.
• ZEUS – Primary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS)
• HORIZON – Effect of Pelacarsen on Cardiovascular Outcomes in Patients With Elevated Lipoprotein(a): Primary Results From the Lp(a) HORIZON Trial
• HORIZON Outcomes Extended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon Trial
LBS.02: Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke
Saturday, Nov. 7, 2026, 1:45 to 2:45 p.m.
• ADJUVANT – Intravenous Tirofiban versus Thrombolysis Before Endovascular Thrombectomy in Acute Ischemic Stroke: The Adjuvant Randomized Clinical Trial (ADJUVANT)
• OCEANIC-STROKE – Outcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score Category (OCEANIC-STROKE)
• REDUCE – A Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After Stroke (REDUCE)
• OPTIMAL-Stroke – Intensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke Trial
LBS.03: Late-breaking Science: Hot Topics in CVD Prevention
Saturday, Nov. 7, 2026, 3:15 to 4:30 p.m.
• STREAM – Discontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical Trial (STREAM)
• OPTIMAL-DIABETES – Intensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES Trial
• eZ-PAVE – Statin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE Trial
• Yoga-CaRe HF – Yoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction
LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care
Sunday, Nov. 8, 2026, 3:30 to 4:45 p.m.
• OptimPacing – Left Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial
• COAST-AF Randomized – Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized Trial
• SUPERIOR – Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial
• RACE-CARS – Randomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary Results
LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction
Monday, Nov. 9, 2026, 8 to 9:15 a.m.
• TYDAL-TIMI 78 – A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations
• CTX310– CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial
• ATTAIN-OSA – Orforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSA
• SYNCHRONIZE-CVOT – Survodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE-CVOT Tri
LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease
Monday, Nov. 9, 2026, 9:45 to 11 a.m.
• WATCH-LV – Consumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home Monitoring
• PROVAR+ – PROVAR+ External Validation Study
• AI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled Trial
• All-Cause and Cardiovascular Mortality in the U.S.: Risk Stratification via Integrated AI-Enabled Coronary Plaque Analysis and FFR-CT in Over 269,000 Patients
AHA is also separately highlighting late-breaking science in featured science sessions, and late-breaking basic science. The featured science sessions will highlight the latest data from studies in various speciality areas of cardiology, including heart failure, acute coronary syndromes, electrophysiology and prevention. The basic science sessions include lab research and pre-clinical studies that may impact the future of cardiac care.
Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]